1Department
of NMR & MRI Facility, All India Institute of Medical Sciences, New
Delhi, Delhi, India; 2Department of Urology, All India Institute
of Medical Sciences, New Delhi, Delhi, India; 3Department of
Radio-diagnosis, All India Institute of Medical Sciences, New Delhi, Delhi,
India; 4Department of Pathology, All India Institute of Medical Sciences,
New Delhi, Delhi, India
The challenge to clinicians in the management of prostate cancer (PCa) patients is the in vivo assessment of disease aggressiveness. TRUS biopsy detects the PCa and determines the Gleason score. Identification of patients with more-aggressive disease would help to prevent overtreatment of those with low-risk tumors. Our results showed the reduction of metabolite ratios [Cit/(Cho+Cr)] and ADC values with the increase of Gleason score. The present study indicates that MRSI and DWI could stratify the PCa disease aggressiveness non-invasively.